Mary Szela has nearly 35 years of experience driving growth and creating value for patients and investors in both the commercial and clinical pharmaceutical arenas.
Mary has served as CEO and President of TriSalus Life Sciences since January 2018. Prior to joining TriSalus, Mary served as Chief Executive Officer of Novelion Therapeutics, a rare disease company, where she led the company through regulatory compliance and legal difficulties, ultimately orchestrating a successful merger and expansion of Aegerion Pharmaceuticals and QLT Therapeutics. Prior to Novelion, she was Chief Executive Officer of Melinta Therapeutics, leading the company’s revitalization effort and accelerating clinical development of its lead asset for treatment of MRSA (methicillin-resistant Staphylococcus aureus).
Previously, Mary held progressive leadership roles at Abbott Laboratories including President of the company’s $8 billion U.S. pharmaceutical business. She developed global brands such as Humira® and served as Senior Vice President for global strategic marketing and services.
Mary currently serves as a member of the Board of Directors for Kura Oncology, Prometheus Biosciences, Omega Therapeutics and Senda Biosciences. She received both her B.S. in Nursing and her MBA from the University of Illinois at Chicago.
